The therapuetic impact of 18F-FDG whole body PET: A radiooncologist's view;Der einfluss der 18F-FDG-Ganzkörper-PET auf das therapuetische management onkologischer patienten aus strahlentherapuetischer sicht

NuklearMedizin

Volumn 44, Issue 1, 2005, Pages 8-14

  Dietl, B ^a   Marienhagen, Jörg ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

FDG PET; Patient management; Radiation oncology; Radiation therapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; BREAST CANCER; CANCER; CANCER RADIOTHERAPY; CARCINOMA; FEMALE; GASTROINTESTINAL TUMOR; HEAD AND NECK CANCER; HUMAN; LUNG CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SARCOMA; TREATMENT PLANNING; TUMOR RECURRENCE; TUMOR VOLUME; UNIVERSITY HOSPITAL; WHOLE BODY RADIATION; ARTICLE; BIOPSY; METHODOLOGY; NEOPLASM; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING;

BIOPSY; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; WHOLE-BODY IRRADIATION;

EID: 14644412815     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1623920     Document Type: Review

References (16)

1. Follow-up after treatment for breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 1998; 158: S65-70.
2. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 2001; 12: 1047-8.
3. 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003; 44: 24-9.
4. Engert A, Schiller P, Josting A et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-8.
5. Erdi YE, Macapinlac H, Rosenzweig KE et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000; 27: 861-6.
6. Erdi YE, Rosenzweig K, Erdi AK et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002; 62: 51-60.
7. Fertig DL, Hayes DF. Considerations in using tumor markers: what the psycho-oncologist needs to know. Psychooncology 2001; 10: 370-9.
8. Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 15-93.
9. Hermanek P, Sobin LH, Fleming ID. What do we need beyond TNM? Cancer 1996; 77: 815-7.
10. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001; 19: 111-8.
11. Mackillop WJ, O'Sullivan B, Gospodarowicz M. The role of cancer staging in evidence-based medicine. Cancer Prev Control 1998; 2: 269-77.
12. Marienhagen J, Eilles C. Critical appraisal of diagnostic studies in nuclear medicine. Nuklearmedizin 2003; 42: 129-34.
13. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, »Onko-PET III«, 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-23.
14. Thornbury JR. Intermediate outcomes: diagnostic and therapeutic impact. Acad Radiol 1999; 6: S58-65.
15. Tucker R, Coel M, Ko J et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. J Clin Oncol 2001; 19: 2504-8.
16. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG et al. The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000; 55: 317-24.